×
Back to Agenda
Fact or Fiction: Patient Engagement in the Drug Development Process
Session Chair(s)
Robert Paarlberg, MS
Principal, Paarlberg & Associates LLC, United States
Industry Perspective
Learning Objective : Describe benefits of engaging patient and patient advocacy groups in the drug development process; Discuss regulatory agency experiences with including patient and patient advocacy groups in the decision-making process.
Speaker(s)
Michael Maher
Executive Director, US Regulatory Policy and Global Intelligence, Pfizer Inc, United States
Industry Perspective
John Whyte, DrMed, MD, MPH
Chief Medical Officer, WebMD, United States
FDA Perspective
Marcia K. Horn, JD
President and CEO, ICAN, International Cancer Advocacy Network, United States
Patient Perspective
Have an account?